Join the club for FREE to access the whole archive and other member benefits.

Atropos Therapeutics

Biopharmaceutical company focused on discovering and developing drugs against aging disorders and cancer.

Founded in 2018, Atropos is a biotechnology platform company focused on the discovery, development, and commercialization of therapies targeting the formation of senescent cells. The company leverages unexploited insights in senescence biology to discover agents and modalities. This disruptive approach to "aging" disorders targets that which is common to these diseases, the stress-induced accumulation of the senescent cell in various tissues. 

Visit website:


Details last updated 25-Nov-2020

People at Atropos Therapeutics

Andrew Koff

Professor at Memorial Sloan-Kettering Cancer Center and founder of Atropos Therapeutics.

Atropos Therapeutics News

LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play


Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...

Topics mentioned on this page:
Senescent Cells, Cancer